Cellectar Biosciences Inc's Comment on Sales, Marketing and Customers
Customers billing federal healthcare programs for products include U.S. licensed physicians—such as doctors, dentists, optometrists, podiatrists, and chiropractors—teaching hospitals, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives. Payments and transfers of value to these recipients are reported under the federal Physician Payments Sunshine Act.
: Pancreatic cancer (PC) presents one of the most formidable challenges in oncology, characterized by late-stage diagnosis, rapid progression, and limited treatment options. Recent advances in radiopharmaceuticals have ignited interest in targeted therapies for this malignancy. This article examines the promising preclinical findings of CLR 225 (225Ac-phospholipid ether) presented by Cellectar Biosciences at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research. The data underscore CLR 225 s potential for meaningful tumor growth inhibition and survival benefit, expanding the therapeutic landscape for pancreatic cancer and offering hope for improved patient outco...
Cellectar Biosciences, a leading clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of innovatively prepared drugs for cancer treatment, has declared their alliance with MiBA, a data subsidiary of the American Oncology Network. This partnership aims at promoting the advanced treatment of Waldenstrom s Macroglobulinemia (WM), particularly in the community setting. Such initiative aligns with Cellectar s ongoing efforts to reconstitute the landscape of WM treatment, especially through the commercialization strategy of Iopofosine I 131.Waldenstrom s Macroglobulinemia is a rare and slow-growing type of non-Hodgkin lymphoma, causing an excessive production of a ...
Cellectar Biosciences Inc’s Comment on Sales, Marketing and Customers
Customers billing federal healthcare programs for products include U.S. licensed physicians—such as doctors, dentists, optometrists, podiatrists, and chiropractors—teaching hospitals, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives. Payments and transfers of value to these recipients are reported under the federal Physician Payments Sunshine Act.
Sources:
Cellectar Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cellectar Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Cellectar Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
